NEWS DESK
Building your stock news briefing…
Amgen Inc. - Common Stock (AMGN) is currently showing a slightly bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
/PRNewswire/ -- Компания Amgen (NASDAQ: AMGN) сегодня объявила, что Европейская комиссия (ЕК) выдала регистрационное удостоверение на препарат IMDYLLTRA
THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m.
Most people think you can't time the market. That's nonsense.
This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA ® in IgG4-RD Real-World Evidence Supports TAVNEOS ® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated Vasculitis THOUSAND OAKS, Calif., June 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.
Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
Amgen's recent approval from the European Commission for its drug IMDYLLTRA® to treat early-stage small cell lung cancer marks a notable regulatory milestone, potentially expanding the company's oncology footprint in Europe. This development is the dominant catalyst influencing Amgen's slightly bullish news sentiment, though there is no clear impact yet reflected in earnings tone or major price movements. With mixed trend signals and lacking definitive technical cues like RSI or moving average position, investors may be watching for uptake in market reaction following this approval along with insights from the upcoming Jefferies Global Healthcare Conference presentation. The market will likely await further data on sales potential and competitive positioning of IMDYLLTRA before adjusting expectations significantly.
AMGN is not giving a fully clean trend read right now, which makes the quality of follow-through especially important.
Momentum is not especially stretched right now, so price behaviour around fresh headlines may matter more than an extreme oscillator reading.
Last price is $325.98, versus MA50 at — and MA200 at —. Relative to those reference points, AMGN is — vs MA50 and — vs MA200.
/PRNewswire/ -- Компания Amgen (NASDAQ: AMGN) сегодня объявила, что Европейская комиссия (ЕК) выдала регистрационное удостоверение на препарат IMDYLLTRA
THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m.
Most people think you can't time the market. That's nonsense.